Natco launches cut price versions of cancer drug ibrutinib in india
Posted by
www.biotecnika.org
The patent for the drug is held by Pharmacyclics for three to four
more years in India. Pharmacyclics was globally acquired by US giant
AbbVie in 2015 in a massive USD21 billion deal. Natco's latest move is
consistent with its earlier launches and challenging the patents held
on anti-cancer drugs by multinational drug companies.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-versions-of-cancer-drug-ibrutinib-in-india/articleshow/72894811.cms
Subscribe to:
Post Comments (Atom)
April 2, 2021 at 12:21 AM
Thank you for sharing this informative blog. https://www.genuinedrugs123.com/186-Anti-Cancer-Drugs-Generic-Ibrutinib-Brand-Imbruvica.aspx
Post a Comment